Cancer Patients Referred to do PET/CT StudyNCT07306975
Comparative Analysis of SUV Measurements Using Different Correction Methods in Oncological PET/CT Imaging.
An observational study of Cancer Patients Referred to do PET/CT Study, run by Assiut University.
Trial summary
-To measure SUVs by using different correction methods in oncological PET/CT imaging. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer Patients Referred to do PET/CT Study
- What is being tested?
- PET/CT with 18-FDG
- Type of treatment
- Injection or infusion, Medical device
- How many people
- 80 participants
- Where
- No sites listed yet
- Study dates
- 10 Dec 2025to 1 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: - Cancer patients (> 18 years old) referred to nuclear medicine unit to do F18-FDG PET/CT study.
Who may be able to join
- Cancer patients (> 18 years old) referred to nuclear medicine unit to do F18-FDG PET/CT study.
Who cannot join
- Patients < 18 years old.
- Patients with increased FDG uptake on tissue associated with non-malignant causes such as diffuse bone marrow FDG uptake or inflammatory.
- Patients with extensive metastasis.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
HebatAllah Ahmed AbdelRaoof Askar, Assistant Professor, doctor contact
About this study
-To measure SUVs by using different correction methods in oncological PET/CT imaging.
Read the detailed description
-To compare between SUV measurements in the tumor and liver using different standardizing parameters such as: body weight, lean body mass and body surface area.
- Being tested
- PET/CT with 18-FDG
- Keywords
- SUV measurements , correction, PET/CT
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PET/CT with 18-FDGDevice
- Patients will fast for at least 4 hrs before imaging with blood glucose level (<200 mg/dl) before intravenous administration of F18-FDG.
- Imaging will be performed approximately 45 to 60 min after 18F-FDG injection, an imaging field of view from the base of skull to mid-thighs with the arms above the head whenever possible is used or otherwise the arms are positioned beside the body.
What is being measured
The primary outcome is the main question the study is designed to answer.
-To measure SUVs by using different correction methods in oncological PET/CT imaging.
-To compare between SUV measurements in the tumor and liver using different standardizing parameters such as: body weight, lean body mass and body surface area.
Measured: 1/12/2025 to 1/10/2027
Secondary outcomes (1)
To determine if SUVbsa is more accurate than SUVbw in obese patients.
-To determine if ''normalization of FDG uptake for the body surface area'' (SUVbsa) is independent of the patient's body size and is more reliable than SUVbw.
Measured: 1/12/2025 to 1/10/2027
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Dec 2025
- Study start10 Dec 2025 (estimated)
- Primary completion1 Oct 2027 (estimated)
- Study completion1 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Cancer Patients Referred to do PET/CT StudyStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Aya Kamel Hamed Ahmed, Assiut University
- Investigators
- Hanan Gamal Eldin Mostafa, Professor, doctor, Study chair, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07306975
- Sponsor's protocol ID
- SUV measurements in PET/CT
- Status last verified
- Dec 2025
- First submitted
- 13 Dec 2025
- Last updated
- 29 Dec 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Publications
Kim CK, Gupta NC, Chandramouli B, Alavi A. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med. 1994 Jan;35(1):164-7.
PubMed 8271040Nakaichi T, Funamoto K, Yamashita S, Yamamoto H, Yokoyama K. Clinical Usefulness of Standardized Uptake Value Normalized to Lean Body Mass Measured Using a Body Composition Analyzer. Cureus. 2025 May 30;17(5):e85089. doi: 10.7759/cureus.85089. eCollection 2025 May.
PubMed 40589668Azmi NHM, Suppiah S, Liong CW, Noor NM, Said SM, Hanafi MH, et al. Reliability of standarized uptake value normalized to lean body mass using the liver as a reference organ, in contrast-enhanced 18F-FDG PET/CT imaging. Radiography. 2018;24(2):112-117. doi:10.1016/j.radi.2017.09.006.
Ahmed A, Ali M, Salah H, Eisa RE, Mohieldin H, Omer H, et al. Evaluation of uptake values of FDG: Body surface area Vs. body weight correction. Radiat Phys Chem. 2022;201:110482. doi:10.1016/j.radphyschem.2022.110482 .
Study at a glance
From the registry record, last updated by the sponsor on 29 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Analysis of SUV Measurements Using Different Correction Methods in Oncological PET/CT Imaging.
- ClinicalTrials.gov ID
- NCT07306975
- Acronym / sponsor ID
- SUV measurements in PET/CT
- Keywords
- SUV measurements , correction, PET/CT
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 10 Dec 2025 (estimated)
- Primary completion
- 1 Oct 2027 (estimated)
- Study completion
- 1 Dec 2027 (estimated)
- First posted
- 29 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
-To measure SUVs by using different correction methods in oncological PET/CT imaging.
Detailed description
-To compare between SUV measurements in the tumor and liver using different standardizing parameters such as: body weight, lean body mass and body surface area.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- - Cancer patients (> 18 years old) referred to nuclear medicine unit to do F18-FDG PET/CT study.
Key inclusion criteria (1 listed)
- Cancer patients (> 18 years old) referred to nuclear medicine unit to do F18-FDG PET/CT study.
Key exclusion criteria (3 listed)
- Patients < 18 years old.
- Patients with increased FDG uptake on tissue associated with non-malignant causes such as diffuse bone marrow FDG uptake or inflammatory.
- Patients with extensive metastasis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PET/CT with 18-FDG* Patients will fast for at least 4 hrs before imaging with blood glucose level (<200 mg/dl) before intravenous administration of F18-FDG. * Imaging will be performed approximately 45 to 60 min after 18F-FDG injection, an imaging field of view from the base of skull to mid-thighs with the arms above the head whenever possible is used or otherwise the arms are positioned beside the body. | Device | – |
Primary outcome
-To measure SUVs by using different correction methods in oncological PET/CT imaging.
Time frame: 1/12/2025 to 1/10/2027
-To compare between SUV measurements in the tumor and liver using different standardizing parameters such as: body weight, lean body mass and body surface area.
1 secondary outcome
To determine if SUVbsa is more accurate than SUVbw in obese patients.
Time frame: 1/12/2025 to 1/10/2027
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Dec 2025.
- Results publication: PubMed 8271040Kim CK, Gupta NC, Chandramouli B, Alavi A. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med. 1994 Jan;35(1):164-7.
- Results publication: PubMed 40589668Nakaichi T, Funamoto K, Yamashita S, Yamamoto H, Yokoyama K. Clinical Usefulness of Standardized Uptake Value Normalized to Lean Body Mass Measured Using a Body Composition Analyzer. Cureus. 2025 May 30;17(5):e85089. doi: 10.7759/cureus.85089. eCollection 2025 May.
- Results publicationAzmi NHM, Suppiah S, Liong CW, Noor NM, Said SM, Hanafi MH, et al. Reliability of standarized uptake value normalized to lean body mass using the liver as a reference organ, in contrast-enhanced 18F-FDG PET/CT imaging. Radiography. 2018;24(2):112-117. doi:10.1016/j.radi.2017.09.006.
- Results publicationAhmed A, Ali M, Salah H, Eisa RE, Mohieldin H, Omer H, et al. Evaluation of uptake values of FDG: Body surface area Vs. body weight correction. Radiat Phys Chem. 2022;201:110482. doi:10.1016/j.radphyschem.2022.110482 .
- Individual participant dataSharing planned: Yes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
HebatAllah Ahmed AbdelRaoof Askar, Assistant Professor, doctor contact
Hanan Gamal Eldin Mostafa, Professor, doctor study chair
Assiut University
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer Patients Referred to do PET/CT Study, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact HebatAllah Ahmed AbdelRaoof Askar, Assistant Professor, doctor (+2001003040898, hebaaskar@aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
-To measure SUVs by using different correction methods in oncological PET/CT imaging. (time frame: 1/12/2025 to 1/10/2027). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07306975, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Dec 2025.